# A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Who Are Currently on Metformin Monotherapy

> **NCT00674466** · PHASE2 · COMPLETED · sponsor: **ConjuChem** · enrollment: 90 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** 1.5 mg or 2.0 mg CJC-1134-PC
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00674466
- **Lead sponsor:** ConjuChem
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2017-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00674466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00674466, "A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Who Are Currently on Metformin Monotherapy". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00674466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*